PortfoliosLab logoPortfoliosLab logo
China Pharma Holdings, Inc. (CPHI)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US16941T1043
CUSIP
16941T104
IPO Date
Apr 17, 2002

Highlights

Market Cap
$2.36M
Enterprise Value
$1.29B
EPS (TTM)
-$182.59K
Total Revenue (TTM)
$756.22B
Gross Profit (TTM)
-$59.65B
EBITDA (TTM)
$378.77B
Year Range
$0.50 - $2.65
ROA (TTM)
-4.12%
ROE (TTM)
-7.84%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


China Pharma Holdings, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in China Pharma Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

China Pharma Holdings, Inc. (CPHI) has returned -49.59% so far this year and -76.81% over the past 12 months. Over the last ten years, CPHI has returned -39.31% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


China Pharma Holdings, Inc.

1D
-0.46%
1M
6.46%
YTD
-49.59%
6M
-68.72%
1Y
-76.81%
3Y*
-68.49%
5Y*
-73.53%
10Y*
-39.31%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Apr 17, 2002, CPHI's average daily return is +0.15%, while the average monthly return is +0.82%. At this rate, your investment would double in approximately 7.1 years.

Historically, 37% of months were positive and 63% were negative. The best month was Jan 2003 with a return of +325.0%, while the worst month was Apr 2003 at -76.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CPHI closed higher 36% of trading days. The best single day was Jan 8, 2003 with a return of +325.0%, while the worst single day was Apr 7, 2003 at -80.4%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-6.61%-49.29%6.46%-49.59%
2025-6.11%-3.85%25.35%-18.28%-25.58%11.88%-4.47%-18.71%40.29%-15.90%-2.44%-24.37%-47.96%
2024-23.97%-20.65%1.67%-17.26%-3.63%-16.02%-21.13%3.01%17.04%9.39%-22.63%16.25%-61.57%
202311.57%-37.01%-42.14%-7.69%-5.47%0.24%-5.48%-50.37%-7.50%-37.70%22.67%6.98%-87.38%
2022-15.04%6.83%-10.96%-28.46%-16.81%-7.54%-1.40%-7.75%-33.40%-3.77%-3.52%-20.55%-80.13%
202159.38%24.88%-5.33%-8.33%-23.38%22.58%12.00%-15.33%-18.56%15.97%-4.28%-22.16%8.25%

Benchmark Metrics

China Pharma Holdings, Inc. has an annualized alpha of 40.25%, beta of 0.57, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since April 18, 2002.

  • This stock participated in 186.04% of S&P 500 Index downside but only -3.21% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.57 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
40.25%
Beta
0.57
0.01
Upside Capture
-3.21%
Downside Capture
186.04%

Return for Risk

Risk / Return Rank

CPHI ranks 5 for risk / return — in the bottom 5% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


CPHI Risk / Return Rank: 55
Overall Rank
CPHI Sharpe Ratio Rank: 77
Sharpe Ratio Rank
CPHI Sortino Ratio Rank: 66
Sortino Ratio Rank
CPHI Omega Ratio Rank: 66
Omega Ratio Rank
CPHI Calmar Ratio Rank: 33
Calmar Ratio Rank
CPHI Martin Ratio Rank: 55
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for China Pharma Holdings, Inc. (CPHI) and compare them to a chosen benchmark (S&P 500 Index).


CPHIBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.86

0.90

-1.76

Sortino ratio

Return per unit of downside risk

-1.43

1.39

-2.82

Omega ratio

Gain probability vs. loss probability

0.81

1.21

-0.40

Calmar ratio

Return relative to maximum drawdown

-0.98

1.40

-2.38

Martin ratio

Return relative to average drawdown

-1.69

6.61

-8.29

Explore CPHI risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


China Pharma Holdings, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the China Pharma Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the China Pharma Holdings, Inc. was 100.00%, occurring on Mar 20, 2026. The portfolio has not yet recovered.

The current China Pharma Holdings, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Apr 25, 20026015Mar 20, 2026

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of China Pharma Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how China Pharma Holdings, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CPHI relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CPHI has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for CPHI in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CPHI has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items